Barclays PLC Recursion Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 697,432 shares of RXRX stock, worth $5.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

697,432

Previous 697,432 -0.0%

Holding current value

$5.05 Million

Previous $4.6 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$5.92 - $8.6 $1.8 Million - $2.62 Million	304,278 Added 77.39%	697,432 $4.6 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $579,569 - $792,472	78,853 Added 25.09%	393,154 $2.95 Million
Q1 2024 May 15, 2024	SELL	$9.13 - $15.52 $2.58 Million - $4.38 Million	-282,257 Reduced 47.31%	314,301 $3.13 Million
Q4 2023 Feb 15, 2024	BUY	$5.09 - $10.79 $197,425 - $418,511	38,787 Added 6.95%	596,558 $5.88 Million
Q3 2023 Nov 07, 2023	BUY	$6.59 - $15.86 $2.43 Million - $5.85 Million	369,103 Added 195.64%	557,771 $4.27 Million
Q2 2023 Aug 03, 2023	BUY	$4.56 - $9.94 $2,033 - $4,433	446 Added 0.24%	188,668 $1.41 Million
Q1 2023 May 04, 2023	SELL	$6.42 - $9.64 $695,786 - $1.04 Million	-108,378 Reduced 36.54%	188,222 $1.26 Million
Q4 2022 Feb 13, 2023	BUY	$7.16 - $12.7 $1.32 Million - $2.34 Million	184,366 Added 164.27%	296,600 $2.29 Million
Q3 2022 Nov 03, 2022	BUY	$7.83 - $13.6 $718,496 - $1.25 Million	91,762 Added 448.23%	112,234 $1.2 Million
Q2 2022 Aug 12, 2022	SELL	$5.04 - $9.26 $12,882 - $23,668	-2,556 Reduced 11.1%	20,472 $166,000
Q1 2022 May 16, 2022	BUY	$6.16 - $18.03 $141,852 - $415,194	23,028 New	23,028 $165,000

Others Institutions Holding RXRX

# of Institutions

286

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.31B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account